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The incidence of melanoma has increased over the last 40 years,
more so than for any other tumour. It is now responsible for 7500
deaths annually in the USA. Although there have recently been
interesting developments in the adjuvant treatment of surgically
resected high-risk disease, the outlook for patients with advanced
unresectable melanoma remains dismal. A minority of patients
respond to treatment, remissions are generally only short-lived,
and median overall survival is around 6 months (Balch et al,
1997). For many years dacarbazine has been the standard
chemotherapy for melanoma, despite a response rate of only 20%
and no discernible impact on survival (Lee et al, 1995). The
relative ineffectiveness of single-agent treatment has led to consid-
erable interest in multi-agent chemotherapy regimens, and in
combining chemo- and biotherapy.
In 1984, del Prete reported the results of 20 patients treated with
dacarbazine, BCNU, cisplatin and tamoxifen (DBCT). This four-
drug combination, also known as the Dartmouth regimen, has
since been at the forefront of attempts to improve response rates to
chemotherapy and overall survival in patients with advanced
melanoma. Although early studies observed response rates in
excess of 50%, these have generally been in small numbers of
patients (del Prete et al, 1984; McClay et al, 1992). To date 
no significant impact on overall survival has been reported, but
long-term remissions have been described in some responders.
However, until recently no randomized study had been published
comparing DBCT with single-agent dacarbazine chemotherapy.
Despite this, many centres have adopted DBCT as their standard
therapy in advanced melanoma.
We designed a randomized phase III study to examine response
rate and survival in patients treated with DBCT in comparison
with a standard treatment of dacarbazine and interferon. We
elected to use the latter regimen as our standard therapy as, at the
time the trial was designed, there were reports to suggest that it
was more effective than dacarbazine alone (Falkson et al, 1991).
Improvements in survival, if seen, would need to be offset against
the anticipated increase in toxicity and the need for hospitalization
with multi-agent treatment. Thus, we decided to record the impact
of DBCT on time spent in hospital during treatment, to help deter-
mine any extra costs associated with using DBCT.
PATIENTS AND METHODS
Patients
Adults (aged 18 years or more) with measurable advanced malig-
nant melanoma were eligible for inclusion. Adequate performance
status (Karnofsky score [KP] 50 or greater) and renal (creatinine
clearance > 50 ml min–1), hepatic (total bilirubin < 1.5 ´ the upper
limit of laboratory normal [ULN], aspartate aminotransferase
[AST] < 3 ´ ULN, alkaline phosphatase ≤ 3 ´ ULN), and bone
marrow (absolute neutrophil count [ANC] ³ 1500 mm–3, platelets
³ 100 000 mm–3, haemoglobin ³ 10 g dl–1) functions were
required. Prior therapy for metastatic melanoma was not
permitted, with the exception of isolated limb perfusion or local
radiotherapy for symptom control – so long as there was measur-
able disease beyond the treatment area. Patients with overt central
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medical risk were excluded from the study. Individuals who had
not recovered from previous treatment or who suffered from
previous or concurrent malignancies at other sites were also
excluded. Local ethical review committees approved the study. All
patients gave written informed consent prior to randomization.
Treatment
Patients were randomized through the Statistics Department at 
the Christie Hospital to receive either dacarbazine/interferon
(DTIC/IFN) or DBCT. In the control arm, dacarbazine was admin-
istered intravenously (i.v.) on day 1 at a dose of 800 mg m–2, and
treatment was repeated every 21 days. IFN-a2a was given by
subcutaneous injection at 9 Miu thrice weekly throughout the
treatment period. Dose delay, not reduction, was practised when
blood counts had not recovered at the time of planned re-treatment
with dacarbazine. This was permitted when ANC > 1500 mm–3
and platelets > 100 000 mm–3. For the DBCT regimen dacarbazine
and cisplatin were administered i.v. on days 1–3 at daily doses of
220 and 25 mg m–2 respectively, with treatment being repeated
every 21 days. BCNU was given i.v. at a dose of 150 mg m–2 on
day 1 and repeated every second cycle (i.e. every 42 days).
Tamoxifen 20 mg was administered daily by mouth throughout
treatment. Again, dose delay was practised when blood counts had
not recovered at the time of planned re-treatment, with the same
criteria as for DTIC/IFN. Treatment continued until unacceptable
toxicity (as determined by individual investigators) or disease
progression occurred, or for a maximum of six cycles. Both treat-
ments were delivered in hospital, with DTIC/IFN generally
requiring a 1-day admission and DBCT a 2-day stay.
Study evaluations
Radiological and clinical evaluation of measurable sites of disease
was required prior to randomization and after cycles 3 and 6.
Where lesions were measurable on chest X-ray or abdominal
ultrasound scan computerized tomography was not mandated.
Responses were evaluated according to standard World Health
Organization criteria. Toxicity was assessed and graded each cycle
according to the Common Toxicity Criteria. In addition, the time
spent in hospital was noted for each patient, without differentiating
between admissions due to disease-related problems, treatment
administration or toxicities.
Statistical considerations
The primary objectives of the study were to compare response rate
and 1-year survival between patients treated with either dacar-
bazine/interferon or DBCT, on an intention-to-treat basis. Survival
was measured from the date of randomization to the date of death
or last follow-up. Secondary objectives were to assess the median
overall survival, toxicity and time spent in hospital for the two
treatments. Recruitment of 100 patients was planned, to allow
detection of a 25% absolute difference in survival at 1 year
between arms in a two-tailed test, and a 25% difference in
response rate with 80% power. Kaplan–Meier plots of survival
were constructed, and these were compared using the log-rank test.
Toxicities in each arm were evaluated by the c2 test, and differ-
ences in hospital stay were assessed using a two-tailed 
Mann–Whitney  U-test.
RESULTS
Between 15 September 1994 and 15 June 1998, 105 patients were
enrolled in the study, with 52 assigned to DTIC/IFN and 53 
to DBCT chemotherapy. Five patients were not eligible for 
the study: three did not have metastatic melanoma, one had a prior
malignancy and one lacked histological confirmation of
melanoma. Three further patients did not receive treatment, two
withdrew their consent after randomization, and one deteriorated
rapidly and thus did not start therapy. These eight ineligible and/or
untreated patients were evenly split between the two arms. Patient
characteristics were well balanced between the two groups for
factors known to affect response to therapy and survival (Table 1).
Treatment
Five of the 105 randomized patients received no treatment,
comprising two of the five ineligible patients, and the three who
withdrew consent or deteriorated as described above. Fifty patients
received dacarbazine and IFN, for a median four cycles. Fifty
patients were treated with DBCT, also for a median of four cycles.
Sixty-four of the 178 DBCT cycles given were delayed for toxi-
city, this was significantly more than with DTIC/IFN, where 22 of
194 cycles delivered were delayed (P < 0.01).
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Table 1 Patient characteristics
Dacarbazine/interferon DBCT
n = 52 (%) n = 53 (%)
Age Median 51 51
Range 24–71 24–68
Gender Male 31 (60) 30 (57)
Female 21 (40) 23 (43)
Initial KP 50 1 (2) 3 (6)
60 3 (6) 4 (8)
70 8 (15) 8 (15)
80 16 (31) 14 (26)
90 12 (23) 15 (28)
100 12 (23) 9 (17)
Prior adjuvant interferon therapy 1 (2) 4 (8)
Disease extent No disease evidenta 2 (4) 2 (4)
Soft tissue/LN only 15 (29) 13 (25)
Lung±soft tissue/LN 9 (17) 6 (11)
Visceralb 26 (50) 32 (60)
aThese patients were not eligible (see text). bExcluding lung as the only
visceral site.
Table 2 Response to treatment
Dacarbazine/interferon DBCT
n = 52 (%) n = 53 (%)
Ineligible and untreated 3 (5.8) 4 (7.5)
Not evaluable 3 (5.8) 2 (3.8)
Progressive disease 32 (61.5) 31 (58.5)
Stable disease 5 (9.6) 2 (3.8)
Partial response 5 (9.6) 12 (22.6)
Complete response 4 (7.7) 2 (3.8)
Overall response rate 17.3% 26.4%Response and survival
Response to treatment did not differ significantly between treat-
ment arms, being 17.3% with DTIC/IFN (95% confidence interval
(CI) 8.76–32.0%) and 26.4% with DBCT (95% CI 15.3–40.3%) in
the intention-to-treat population (P = 0.28; Table 2). Median
survival was similar at 199 days with dacarbazine and IFN and
202 days with DBCT (P = 0.39; Figure 1). The 1-year survival was
superior for DTIC/IFN at 30.6% (95% CI 18.5–43.5%) compared
with 22.6% (95% CI 12.8–34.1%) for DBCT, but this was not
statistically significant (P = 0.39). Amongst evaluable patients 
in the treated eligible population response rates were 19.6%
(DTIC/IFN) and 29.8% (DBCT) and, again, were not significantly
different. Responses to standard treatment lasted longer than with
combination therapy (median 394 vs 247 days) but the difference
did not achieve statistical significance (P = 0.07).
Toxicity
Data was available on the toxicity due to treatment for 96 of the
100 treated patients. Two patients were lost to follow-up, and two
others died early of their melanoma before toxicity could be
assessed. In all there were ten deaths on treatment, eight of which
(four in each arm) were ascribed to progressive melanoma. 
There were two treatment-related deaths, both with DBCT: one
patient died of sepsis when neutropenic, and another from 
intra-pulmonary haemorrhage whilst thrombocytopenic.
Haematological toxicity was significantly greater with combina-
tion therapy: six of 50 patients on standard treatment had grade III
or IV toxicity compared with 35 of 46 patients on DBCT. There
were significant differences in the incidence and severity of
anaemia, leucopenia and thrombocytopenia (Table 3). In addition,
seven episodes of neutropenic fever requiring intravenous antibi-
otics were noted in six patients receiving DBCT, but there was
only one such episode with DTIC/IFN. Otherwise, the treatments
were well tolerated and although there was greater non-haemato-
logical toxicity with combination therapy this was only significant
for increase in serum creatinine (Table 4).
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Figure 1 Overall survival in patients treated with dacarbazine and interferon
( ) or with DBCT ( )
Table 3 Haematological toxicity
Dacarbazine/interferon DBCT
n = 50 (%) n = 46 (%)
Maximum grade 0 1 2 3 4 0 1 2 3 4
of toxicity
Anaemiaa 32 (64) 11 (22) 5 (10) 1 (2) 1 (2) 5 (11) 9 (20) 21 (46) 10 (22) 1 (2)
Leucopeniaa 27 (54) 12 (24) 6 (12) 3 (6) 2 (4) 6 (13) 4 (9) 12 (26) 17 (37) 7 (15)
Thrombocytopeniaa 41 (82) 4 (8) 1 (2) 2 (4) 2 (4) 5 (11) 5 (11) 5 (11) 11 (24) 20 (43)
aP < 0.001; c2 test.
Table 4 Non-haematological toxicity
Dacarbazine/interferon DBCT
n = 50 (%) n = 46 (%)
Maximum grade 0 1 2 3 4 0 1 2 3 4
of toxicity
Nausea and vomiting 17 (34) 17 (34) 12 (24) 4 (8) 11 (24) 11 (24) 16 (35) 7 (15) 1 (2)
Diarrhoea 39 (78) 10 (20) 1 (2) 42 (91) 2 (4) 2 (4)
Breathlessness 39 (78) 8 (16) 2 (4) 1 (2) 35 (76) 4 (9) 4 (9) 2 (4) 1 (2)
Stomatitis 43 (86) 7 (14) 40 (87) 4 (9) 2 (4)
Alopecia 42 (84) 5 (10) 1 (2) 2 (4) 31 (67) 9 (20) 4 (9) 2 (4)
Infection 43 (86) 4 (8) 2 (4) 1 (2) 34 (74) 2 (4) 4 (9) 5 (11) 1 (2)
Creatinaemiaa 49 (98) 1 (2) 33 (72) 10 (22) 2 (4) 1 (2)
Bilirubinaemia 46 (92) 3 (6) 1 (2) 42 (91) 2 (4) 2 (4)
Transaminase rise 33 (66) 12 (24) 4 (8) 1 (2) 32 (70) 7 (15) 3 (7) 3 (7) 1 (2)
Alkaline phosphataemia 37 (74) 5 (10) 4 (8) 4 (8) 36 (78) 6 (13) 2 (4) 2 (4)
aP = 0.004; c2 test.Hospitalization
Administration of DBCT required more time spent in hospital than
with standard treatment (on average 2.0 days vs 0.94 days per
cycle), but patients on combination therapy also spent more time in
hospital for reasons other than receiving chemotherapy. On average
DBCT patients spent 3.46 more days per treatment cycle in hospital
(5.75 vs 2.29 days per cycle). When adjusted to account for time
required for treatment delivery, the difference was 2.4 days per
cycle (3.75 with DBCT vs 1.35 on DTIC/IFN). This difference was
statistically significant (P < 0.001), even when adjusted for the time
needed to administer chemotherapy (P < 0.001).
DISCUSSION
To date, the pattern of development of combination therapies in
melanoma has been for promising results in small scale studies,
often at single institutions, which have not then been borne out in
larger or multi-centre trials (Nathanson et al, 1981; Luikart et al,
1984; National Cancer Institute of Canada Melanoma Group,
1984). Thus, there is little randomized controlled trial data to
support the use of combination chemotherapy, and so far non-
randomized data have suggested that although response rates may
be enhanced overall survival is not improved (Lakhani et al, 1990;
Mulder et al, 1994).
This study was conceived after reports of promising results with
the DBCT regimen in advanced melanoma in non-randomized
phase II studies (del Prete et al, 1984; McClay et al, 1992). For the
trial we adhered to the original DBCT regimen, as reported by del
Prete. Other groups have loaded patients with tamoxifen, or spread
treatments over 4-week cycles, but evidence for the superiority of
these changes over the original schedule is lacking. When the trial
was designed there were promising reports of the efficacy of
dacarbazine combined with IFN (Falkson et al, 1991) and we
elected to use this as our standard therapy. Since then other groups
have reported on the utility of dacarbazine and interferon treat-
ment, showing no benefit in terms of response rate or survival over
dacarbazine alone (Bajetta et al, 1994; Falkson et al, 1998). With
these results in mind, although this study compared DBCT with
dacarbazine and IFN, we conclude that standard therapy for
advanced melanoma remains single-agent dacarbazine. This
conclusion is confirmed by the recent results from the Eastern Co-
operative Oncology Group trial comparing DBCT with dacar-
bazine, which also found no enhancement in response rate or
median survival with combination therapy (Chapman et al, 1999).
The response rate and overall survival with the standard therapy
used in this study are in keeping with those reported elsewhere, be
they for DTIC/IFN or dacarbazine alone (Balch et al, 1995). We
found DBCT to be more toxic than DTIC/IFN but tolerable, with
few episodes of neutropenic fever or systemic infection.
Additionally, DBCT treatment necessitated more time in hospital,
an important consideration in a disease where time left to the
patients is short. The toxicity observed agrees with previous expe-
rience of the regimen: for example, we observed grade IV throm-
bocytopenia in 43% of patients, which is comparable with the 44%
seen in the National Cancer Institute of Canada study and the 39%
seen by the Southwest Oncology Group (del Prete et al, 1984;
Rusthoven et al, 1996). McClay and Johnston reported fewer
adverse haematological effects, but in these studies treatments
were administered 4-weekly, and dose reductions were permitted
(McClay et al, 1992; Johnston et al, 1997).
Despite early studies with DBCT reporting response rates in
excess of 50% more recent non-randomized trials, recruiting
greater numbers of patients, have suggested that the true rate in
unselected patients is around 15–30% (Rusthoven et al, 1996;
Johnston et al, 1997; Margolin et al, 1998). Furthermore, no study
to date has shown a survival advantage with this regimen over
dacarbazine alone or with IFN. The 26% overall response rate in
our study is higher than that seen with DTIC/IFN and similar to the
30% reported in the largest published series to date (Rusthoven et
al, 1996). The difference between treatment arms was not statisti-
cally significant and did not result in an improvement in median or
1-year survival. Indeed, median response duration was somewhat
shorter with DBCT than with DTIC/IFN. It should be noted that a
higher proportion than usual (four of nine) of the patients
responding to dacarbazine and IFN had complete responses. It
could be argued that a potential difference in survival between the
treatment arms was masked by patients in the standard arm of the
trial receiving cisplatin and tamoxifen after progression. However,
less than one-third of the patients assigned to this arm went on to
receive further chemotherapy at the time of disease progression,
and none of them responded to second-line treatment.
Furthermore, the overall survival in the DBCT-treated group is
similar to that quoted in the literature for patients receiving single-
agent therapies.
Little has changed in the chemotherapeutic management of
advanced melanoma in the last few years. The standard of care
remains single-agent dacarbazine, with the role of
biochemotherapy yet to be determined. Several phase II studies
have shown impressive response rates and a number of long-term
remissions with combinations of chemotherapy, interleukin-2 (IL-
2) and IFN (Richards et al, 1992; Legha et al, 1996; Atkins, 1997;
Schultz et al, 1997; Thomson et al, 1997). However, these treat-
ments are toxic and complex to deliver, making them unsuitable
for some patients. In any event these results must be treated with
caution until confirmed in randomized phase III trials. To date
there has been only one published comparison of multi-agent
chemotherapy with biochemotherapy. In this IL-2 and IFN
improved upon the response rate observed with cisplatin, dacar-
bazine and tamoxifen, but resulted in poorer median survival
(Rosenberg et al, 1999). Neither result achieved statistical signifi-
cance, although the latter observation brought about early closure
of the trial. There are also randomized phase II data to suggest that
the addition of subcutaneous IL-2 and IFN-a does not enhance the
response rate or median survival of DBCT-treated melanoma
patients (Johnson et al, 1998). If, despite these results, the utility of
this approach can be established – and there are a number of trials
in progress – then the requirement for multiple chemotherapeutic
agents within biochemotherapy regimens will need to be addressed
(Keilholtz et al, 1998).
In conclusion, this study provides no evidence to support the use
of DBCT as standard therapy in advanced melanoma, having
yielded no significant improvement in response rate or survival
compared with dacarbazine and IFN. It would seem inappropriate
to use the four-drug regimen as the control arm in studies of
chemotherapy in combination with biological response modifiers,
notwithstanding any putative interaction between cisplatin and the
latter (Atkins, 1997). Taken in conjunction with the results from
the recent large cooperative group study (Chapman et al, 1999),
our findings suggest that the standard of care for advanced
metastatic melanoma remains single-agent dacarbazine.
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